Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.
Emerging Trends In Cancer Therapy And Supportive Care: Practical Insights For Clinicians
To provide oncology nurses and oncology physician assistants with up-to-date information on their role in the treatment and management of patients with cancer-related anemia, neutropenia, and mucositis.
This activity is designed for oncology nurses and oncology physician assistants.
No prerequisites required.
The Institute for Johns Hopkins Nursing and Johns Hopkins University School of Medicine take responsibility for the content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, the participant should be able to:
- Examine new data on emerging oncology products.
- Describe how the new data should affect patient care.
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center's Commission on Accreditation.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
This 0.6 contact hour Educational Activity (Provider Directed/Learner Paced) is provided by The Institute for Johns Hopkins Nursing. (50 minutes of contact = 1 contact hour.)
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The estimated time to complete this educational activity: 30 minutes.
Release date: December 15, 2006. Expiration date: December 15, 2008.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of The Institute for Johns Hopkins Nursing and the Johns Hopkins University School of Medicine names implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
This program is supported by an educational grant from Amgen Inc.
Full Disclosure Policy Affecting CE Activities:
As a provider accredited by the American Nurses Credentialing Center (ANCC), it is the policy of The Institute for Johns Hopkins Nursing to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Directors and Participating Faculty reported the following:
MiKaela Olsen, RN, MS, OCN
Oncology and BMT Clinical Nurse Specialist
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins Hospital
• Ms Olsen reports serving on the speakers' bureaus for Amgen Inc., GlaxoSmithKline, and Merck & Co., Inc.
Scott W. Possley, PA-C, MPAS
Oncology and BMT Physician Assistant
New York Presbyterian Hospital
Weill Cornell Medical Center
New York, New York
• Mr Possley reports holding stock in CuraGen Corporation; and receiving honoraria from Amgen Inc.
Jerry L. Spivak, MD
Professor of Medicine and Oncology
Johns Hopkins University School of Medicine
Director, Center for Chronic Myeloproliferative Disorders
The Johns Hopkins Hospital
• Dr Spivak reports serving as a consultant for FibroGen, Inc., Novartis, Roche Pharmaceuticals, and Shire Pharmaceuticals.
Pamela Hallquist Viale, RN, MS, CS, ANP, AOCNP
Oncology Nurse Practitioner
Camino Medical Group
• Ms Viale reports serving as a consultant for the Institute for Medical Education & Research, Meniscus, and Pfizer, Inc; and receiving honoraria from and serving on the speakers' bureaus for the Institute for Medical Education & Research, Meniscus, Merck & Co., Inc., Novartis, and Pfizer, Inc.
Gail Wilkes, MS, RNC, AOCN
Oncology Nurse Specialist
Boston Medical Center
• Ms Wilkes reports serving as a consultant for Sanofi-Aventis; holding stock in Genentech; receiving honoraria from Roche Pharmaceuticals; and serving on the speakers' bureaus for INCE (Roche Pharmaceuticals), Meniscus (Sanofi-Aventis), and OES (Genentech).
Notice: No faculty member has indicated that his/her article will reference unlabeled/unapproved uses of drugs or devices.
Johns Hopkins Advanced Studies in Nursing provides disclosure information from contributing authors, lead presenters, and participating faculty. Johns Hopkins Advanced Studies in Nursing does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.
Emerging Trends In Cancer Therapy And Supportive Care: Practical Insights For Clinicians–Part FIVE: Clinical Data for New Oncology Products
MiKaela Olsen, RN, MS, OCN,* Jerry L. Spivak, MD,† and Scott W. Possley, PA-C, MPAS‡
An estimated 33% of women and up to 50% of men in the United States will develop cancer at some point in their lives.1 Furthermore, approximately 1.4 million new cases of cancer and nearly 570 000 deaths because of cancer will occur in the United States in 2006.2 Yet, as staggering as these statistics are, the overall incidence rates of cancer have stabilized3 and mortality rates have been declining since the mid 1970s.3,4 These developments have been attributed to major research advances and ongoing clinical trials for new standards of cancer care.5 Advances made in the areas of targeted therapies, combination therapies, and supportive care agents have not only resulted in increased survival rates, but also may result in improved patient quality of life due to fewer treatment-associated side effects.5,6
In this, the final issue of our 5-part Johns Hopkins Advanced Studies in Nursing series on cancer therapy and supportive care, we examine these recent advances in cancer therapy and the impact on oncology nurse practitioners (NP) and oncology physician assistants (PA). The issue opens with a review article by Pamela Hallquist Viale, RN, MS, CS, ANP, AOCNP, in which she provides up-to-date data on agents newly approved by the US Food and Drug Administration and therapies in development for cancer treatment and management. Her review includes information on select targeted, combination, and supportive care agents for the treatment of solid malignancies.
Also included is a clinician interview with Gail Wilkes, MS, RNC, AOCN, examining the implications of data from recent clinical trials for new oncology products as it applies to clinical practice. She also discusses the challenges that these developments pose for oncology NPs and oncology PAs.
Additionally, Ms Viale and Ms Wilkes each contribute a case study illustrating the effects of novel cancer therapies on patient care in clinical practice. Please note, because of the space constraints of this issue, Ms Viale and Ms Wilkes will focus only on those agents that have completed phase II or phase III clinical trials for the treatment of patients with solid malignancies.
As we conclude our Johns Hopkins Advanced Studies in Nursing series on cancer therapy and supportive care, we hope the information presented has addressed the challenges you face in your clinical practice and, as a result, has enhanced your ability to provide the best care possible for your patients.
The content in this monograph was developed with the assistance of a staff medical writer. Each author had final approval of his/her article and all its contents.
1. Hewitt M, Greenfield S, Stovall E, eds. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: The National Academies Press; 2006. Available at: http://www.iom.edu/CMS/ 28312/4931/30869.aspx. Accessed September 11, 2006.
2. American Cancer Society. Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2006. Available at: http://www.cancer.org/docroot/MED/content/downloads/MED_1_1x_CFF2006_Estimated_New_Cases_Deaths_by_Sex_US.asp. Accessed September 18, 2006.
3. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107:1711-1742.
4. American Cancer Society. Cancer Facts & Figures 2005. Atlanta, Ga: American Cancer Society; 2005. Available at: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf. Accessed October 19, 2006.
5. Herbst RS, Bajorin DF, Bleiberg H, et al. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol. 2006;24:190-205.
6. National Cancer Institute. Targeted Therapies: Questions and Answers. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted. Accessed September 12, 2006.
*Oncology and BMT Clinical Nurse Specialist, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland.
†Professor of Medicine and Oncology, Johns Hopkins University School of Medicine, Director, Center for Chronic Myeloproliferative Disorders, The Johns Hopkins Hospital, Baltimore, Maryland.
‡Oncology and BMT Physician Assistant, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, New York.
Address correspondence to: MiKaela Olsen, RN, MS, OCN, Oncology and BMT Clinical Nurse Specialist, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, The Harry & Jeannette Weinberg Building, 401 North Broadway, Room 5132, Baltimore, MD 21231. E-mail: firstname.lastname@example.org.